Inflammation-Sensitive Plasma Proteins and Incidence of Myocardial Infarction in Men with Low Cardiovascular Risk

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 12, 2003, Pages 2247-2251

  Engström, Gunnar ^a   Stavenow, Lars ^a   Hedblad, Bo ^a   Lind, Peter ^a   Tydén, Patrik ^a   Janzon, Lars ^a   Lindgärde, Folke ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Epidemiology; Inflammation; Myocardial infarction; Risk factors

Indexed keywords

ALPHA 1 ANTITRYPSIN; CERULOPLASMIN; CHOLESTEROL; FIBRINOGEN; HAPTOGLOBIN; INFLAMMATION SENSITIVE PLASMA PROTEIN; LIPID; OROSOMUCOID; PLASMA PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; DIABETES MELLITUS; FOLLOW UP; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFLAMMATION; LIPID BLOOD LEVEL; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; POPULATION RISK; PRIORITY JOURNAL; SMOKING;

ACUTE-PHASE PROTEINS; ALPHA 1-ANTITRYPSIN; CARDIOVASCULAR DISEASES; CERULOPLASMIN; FIBRINOGEN; HAPTOGLOBINS; HUMANS; INCIDENCE; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OROSOMUCOID; RISK FACTORS;

EID: 0348014416     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000102924.11767.8D     Document Type: Article

References (32)

1. Stamler J, Stamler R, Neaton JD, Wentworth D, Daviglus ML, Garside D, Dyer AR, Liu K, Greenland P. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA. 1999;282:2012-2018.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340:115-126.
3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
4. Sakkinen P, Abbott RD, Curb JD, Rodriguez BL, Yano K, Tracy RP. C-reactive protein and myocardial infarction. J Clin Epidemiol. 2002;55: 445-451.
5. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
6. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost. 2003;89:601-609.
7. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, Hack CE. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation. 1999;100:96-102.
8. Greenland P, Gidding SS, Tracy RP. Commentary: Life-long prevention of atherosclerosis: the critical importance of major risk factor exposures. Int J Epidemiol. 2002;31:1129-1134.
9. Engström G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgärde F. The effects of cholesterol and inflammation-sensitive proteins on incidence of stroke and myocardial infarction. Circulation. 2002;105:2632-2637.
10. Berglund G, Nilsson P, Eriksson KF, Nilsson JA, Hedblad B, Kristenson H, Lindgärde F. Long-term outcome of the Malmö preventive project: mortality and cardiovascular morbidity. J Intern Med. 2000;247:19-29.
11. Engström G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgärde F. Long-term effects of inflammation-sensitive plasma proteins and systolic blood pressure on incidence of stroke. Stroke. 2002;33:2744-2749.
12. Lind P, Hedblad B, Stavenow L, Janzon L, Eriksson KF, Lindgärde F. Influence of plasma fibrinogen levels on the incidence of myocardial infarction and death is modified by other inflammation-sensitive proteins: a long-term cohort study. Arterioscler Thromb Vasc Biol. 2001;21: 452-458.
13. Engström G, Stavenow L, Hedblad B, Lind P, Eriksson KF, Janzon L, Lindgärde F. Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke. Diabetes. 2003; 52:442-447.
14. Engström G, Lind P, Hedblad B, Wollmer P, Stavenow L, Janzon L, Lindgärde F. Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation. 2002;106: 2555-2560.
15. Engström G, Lind P, Hedblad B, Berglund G, Stavenow L, Janzon L, Lindgärde F. Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive proteins. Arterioscler Thromb Vasc Biol. 2002;22:2054-2058.
16. Engström G, Hedblad B, Stavenow L, Lind P, Janzon L, Lindgärde F. Inflammations-sensitive plasma proteins are associated with future weight gain. Diabetes. 2003;52:2097-2101.
17. Roschlau P, Bernt E, Gruber W. Enzymatische bestimmung des gesamtcholesterins in serum [in German]. Z Klin Chem Klin Biochem 1974;12: 403-407.
18. Treatment of hyperlipidemia [In Swedish]. Information from the Medical Products Agency in Sweden. 1995;3:178-187.
19. Strategies for the prevention of coronary heart disease: A policy statement of the European Atherosclerosis Society. Eur Heart J. 1987;8:77-88.
20. World Health Organization. International society of hypertension guidelines for the management of hypertension. J Hypertens. 1999;17: 151-183.
21. World Health Organization. 1986 guidelines for the treatment of mild hypertension: memorandum from a WHO/ISH meeting. J Hypertens. 1986;4:383-386.
22. Laurell CB. Electroimmuno assay. Scand J Clin Lab Invest Suppl. 1972; 124:21-37.
23. Engström G, Berglund G, Göransson M, Hansen O, Hedblad B, Merlo J, Tyden P, Janzon L. Distribution and determinants of ischaemic heart disease in an urban population. A study from the myocardial infarction register in Malmö, Sweden. J Intern Med. 2000;247:588-596.
24. Värdering av diagnoskvaliten för akut hjärtinfarkt i patientregistret 1987 and 1995 [in Swedish]. Stockholm, Sweden: The National board of health and welfare; 2000.
25. SPSS Advanced Statistics 7.5. Chicago: SPSS, Inc; 1997.
26. Hashimoto H, Kitagawa K, Hougaku H, Shimizu Y, Sakaguchi M, Nagai Y, Iyama S, Yamanishi H, Matsumoto M, Hori M. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation. 2001;104:63-67.
27. Engström G, Janzon L. Risk of developing diabetes is inversely related to lung function: a population-based cohort study. Diabetic Med. 2002;19; 167-170.
28. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-334.
29. Tracy RP, Arnold AM, Ettinger W, Fried L, Meilahn E, Savage P. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study. Arterioscler Thromb Vasc Biol. 1999;19:1776-1783.
30. Strandberg TE, Tilvis RS. C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. Arterioscler Thromb Vasc Biol. 2000;20:1057-1060.
31. Stefanadis C, Diamantopoulos L, Demellis J, Economou E, Tsiamis E, Toutouzas K, Vlachopoulos C, Toutouzas P. Heat production of atherosclerotic plaques and inflammation assessed by the acute phase proteins in acute coronary syndromes. J Mol Cell Cardiol. 2000;32:43-52.
32. Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, Pestaner J, Smialek J, Virmani R. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation. 2002;105:2019-2023.